Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
According to DRG epidemiology, more than 35 million people in the United States suffer from migraines. Despite being underutilized, migraine prophylaxis is a core treatment approach in reducing migraine frequency, severity, and duration. Prescription options include a diverse mix of on- and off-label oral drugs, newly launched anti-CGRP MAbs (i.e., Amgen / Novartis’s Aimovig, Teva’s Ajovy, and Eli Lilly’s Emgality), and Allergan’s Botox, which the FDA approved specifically for chronic migraine prevention. Prophylaxis is both individualized and dynamic, as physicians adjust regimens to improve outcomes and/or avoid side effects. Understanding this patient journey provides needed context for new and existing players as new preventives establish themselves in the market.
Markets covered: United States
Real-world data: Longitudinal patient-level claims data analysis
Key drugs covered: Aimovig, Ajovy, Emgality, Botox, topiramate IR, Trokendi XR, Qudexy XR, topiramate XR, propranolol, amitriptyline, verapamil, others
Key analysis provided:
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Already a Client? Log in to access this report.
Audreza Das is a Senior Analyst in the CNS/Ophthalmology team at Decision Resources Group She has authored content across indications, including neuropathic pain, age-related macular degeneration, treatment-related depression, painful diabetic neuropathy, and migraine. Ms. Das has previously worked at Novo Nordisk, as a Market Analyst for European markets. Previous experience at a SME, included developing disease competitive landscapes, covering global conferences etc. Ms. Das received her degree in Biotechnology from Birla Institute of Technology, a deemed university and her Diploma in Cancer Immunology & Biotechnology from University of Nottingham.